株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

多発性骨髄腫(カーラー病):パイプライン製品の分析

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229718
出版日 ページ情報 英文 1093 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.29円で換算しております。
Back to Top
多発性骨髄腫(カーラー病):パイプライン製品の分析 Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016
出版日: 2016年12月21日 ページ情報: 英文 1093 Pages
概要

多発性骨髄腫とは、悪性形質細胞が骨髄内部で増殖し、異常な量の特殊タンパク質を産出する、という種類のがんです。その病因についてはまだ明らかにされていません。高齢者が主な発症者となっています。主な症状として、貧血症や出血、神経損傷、皮膚病変、骨の圧痛・疼痛、腎不全などが挙げられます。主な治療法として、化学療法や放射線治療、免疫抑制剤、外科手術などがあります。

当レポートでは、世界各国での多発性骨髄腫(カーラー病)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

多発性骨髄腫の概要

治療薬の開発

  • 多発性骨髄腫向けパイプライン製品:概要
  • 多発性骨髄腫向けパイプライン製品:比較分析

各企業で開発中の多発性骨髄腫治療薬

大学/研究機関で研究中の多発性骨髄腫治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

多発性骨髄腫治療薬:開発中の製品の一覧(企業別)

多発性骨髄腫治療薬:研究中の製品の一覧(大学/研究機関別)

多発性骨髄腫治療薬の開発に従事している企業

多発性骨髄腫:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

多発性骨髄腫治療薬:開発が休止状態の製品

多発性骨髄腫治療薬:開発が中止された製品

多発性骨髄腫関連製品の開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8844IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 61, 60, 2, 114, 22 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 8, 18 and 6 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Multiple Myeloma (Kahler Disease) Overview
  • Therapeutics Development
  • Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies
  • Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes
  • Multiple Myeloma (Kahler Disease) - Pipeline Products Glance
  • Multiple Myeloma (Kahler Disease) - Products under Development by Companies
  • Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes
  • Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
  • Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
  • Drug Profiles
  • Multiple Myeloma (Kahler Disease) - Dormant Projects
  • Multiple Myeloma (Kahler Disease) - Discontinued Products
  • Multiple Myeloma (Kahler Disease) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2016
  • Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by AB Science SA, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ablynx NV, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by ADC Therapeutics Sarl, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Alissa Pharma, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corp, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arcarios BV, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arno Therapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arvinas Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Asana BioSciences LLC, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Astellas Pharma Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by bluebird bio Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis SA, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Biosciences Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Constellation Pharmaceuticals Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Company, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Five Prime Therapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science srl, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by GlycoMimetics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by GlyTR Therapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by GP Pharm SA, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Heidelberg Pharma GmbH, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Hutchison MediPharma Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology LLC, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by ImmunGene Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Immunomedics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corp, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Jasco Pharmaceuticals LLC, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Juno Therapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corp, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kancera AB, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Karus Therapeutics Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kesios Therapeutics Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kite Pharma Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by LG Life Science LTD, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MediGene AG, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MedImmune LLC, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Medivation Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Mesoblast Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax LLC, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nordic Nanovector ASA, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by OncoPep Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by OXIS International Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Peptinov SAS, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar SA, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Phylogica Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Polyphor Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Progenra Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Quimatryx SL, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals SA, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sellas Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Selvita SA, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Theravectys SA, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Tragara Pharmaceuticals Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Verastem Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vivolux AB, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H2 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by XTL Biopharmaceuticals Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..1), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..2), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..3), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..4), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..5), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..6), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..7), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..8), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..9), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..10), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..11), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..12), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..13), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..14), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..15), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..16), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..17), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..18), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..19), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..20), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..21), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..22), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..23), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..24), H2 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..25), H2 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..1), H2 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..2), H2 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..3), H2 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..4), H2 2016

List of Figures

  • Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2016
  • Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top